When it comes to clinical treatment of losing weight, GLP-1 therapy took upon itself the medical sector by storm. What began as using not by celebrities and influential persons on social networks to reduce weight, has become a viral sensation, since type 2 diabetes medicine began the GLP-1 tendency. Novo Nordisk a/s. NYSE: NVO He formulated the treatment of Semaglutide, specially designed for obesity, when they launched Wegovy in June 2021.
Eli Lilly & Co. NYSE: Lly In December 2023, it launched its own double agonist treatment with a double agonist GLP-1/GIP.
Between Novo and Lilly, the GLP-1 industry has become an oligopolia with an even smaller threat from compoundors, such as HIS & HES Health Inc. NYSE: Hims After he was removed from the list of lack of drugs.
However, there was a big noise about the new GLP treatment from Viking Therapeutics Inc. NASDAQ: VKTX This threatens to violate the GLP-1 duopoly.
Why is the double action GLP-1/GIP VK2735 can violate the weight loss market
Viking’s GLP-1 is called VK2735. This is a double agonist of the GLP-1/GIP receptor, similar to a tirzepatide. GLP-1 (glucagono-like peptide-1) and GIP (gastric inhibitory polypeptide) are intestinal hormones responsible for curbing appetite, increasing insulin and ultimately lose weight.
VK2735 is developed as injectable and oral treatment. To become a “blockbuster”, it must correspond to efficiency (large average body loss), tolerance (less side effects) and something unique, such as dosing ease (oral delivery and a shot once a month). Semglutid (Novo) and Tyrzepatide (Lilly) are gold standards. Here are the latest results of weight loss for each medicine:
- Wegovy (Novo Nordisk) had an average weight loss of 14.9% with a weekly injection of 2.4 mg after 68 weeks during his study of phase 3 of stage 1.
- Zepbound (Eli Lilly) had an average weight loss of 20.9% with 15 mg of weekly injection after 72 weeks in his study Phase 3 Surmount-1.
- VK2735 (Viking) had an average weight loss of 14.7% with a weekly injection of 15 mg in just 13 weeks in his study of the phase 2 venture enterprise.
Change the game for speed and dosage
Viking Therapeutics Promotions Today today
$ 97.67
227.41% growthBuy
Based on 13 analysts ratings
| The current price | $ 29.83 |
|---|---|
| High forecast | $ 138.00 |
| Average forecast | $ 97.67 |
| Low forecast | $ 38.00 |
Details of the forecast of viking funds
Various weekly cycles may seem to be a comparison of apples with oranges with different test periods. Comparison of their time with the results of weight loss is a rather wrapping of the head. VK2735 showed lightning -fast weight loss at 13.1% of weight loss adjusted for a placebo in 13 weeks. Compare this with Zepbound, reached 20.1% of the placebo-weighting place in 72 weeks, and Wegovy took 68 weeks for only 12.4% of weight loss with a placebo. The percentage of weight loss with a correction on a placebo takes a weight loss of 14.7% and subtracts 1.7% of the weight loss that takes placebo to ensure a more complete picture.
VK2735 drops the weight twice as fast as ZepBound and 5 times faster than Wegovy. Nevertheless, the change in the game-171-day period of half-life, assuming that they can be inject once a month compared to weekly injections for officials. This is addressed not only to patients who want faster weight loss and less painful injections, but also to health insurers who can ultimately choose shorter compensation periods, depending on pricing. This is that excited analysts so as to release a high target price of $ 138 and the target price of an analyst in the amount of $ 97.67 before the approval of the FDA. Viking will conduct its phase 3 injection test in the second quarter of 2025.
Why GLP-1 procedures are the largest masters of money for pharmaceutical giants
Analysts, according to estimates, the GLP-1 drug market to increase from $ 90 billion to $ 150 billion by 2030. GLP-1 novo preparations have semi-Glutid as an active ingredient, while Lilly has a tirzepatide. These GLP-1 processes have grown to explain the largest parts of income. In 2024, Novo Nordisk announced a total income of $ 40.66 billion. USA, of which 20.88 billion dollars. The United States was associated with its GLP-1 drugs, which accounted for 51.4% of the total income. For Eli Lilly, the total income of 2024 amounted to 45.04 billion dollars. The United States, of which GLP-1 medicines brought $ 16.4 billion. USA, which is 37% of the total income.
Blockbuster in the creation: Long -term CDMO transaction is signed
In long-term studies, Zepbound is still a leader, but over time VK2735 can even surpass a weight loss of 20.1% Zepbound for 72 weeks. VK2735 had 13.1% of weight loss in just 13 weeks; If it can reach 20% of weight loss with a placebo in less than 72 weeks, which is almost confidence, since the 13-week study did not have a plateau, then Viking has a blockbuster in the hands of Viking. Viking is also quite confident to sign a long -term transaction with Cordenpharma, the organization for the development and production of contracts (CDMO), to develop its compounds of injection and oral preparations VK2735.
Before considering the Viking therapy, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market wins … and there was no wiking therapy on the list.
While Viking Therapeutics currently has a purchase rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Want to make a profit from the mega-train electric car? Enter your email address, and we will send you our list from which EV shares show the most long -term potential.
Get this free report